In EGFR‐driven lung adenocarcinomas, EGFR pathway activation limited antitumor immunity by upregulating expression of PD‐1, PD‐L1, and inflammatory cytokines, as well as down‐regulating CTLs, which drives immune escape [22]. The gene discussed is EGFR; the disease is lung adenocarcinoma.